期刊文献+

海洋来源真菌Penicillium citrinum中的一个新桔霉素衍生物(英文) 被引量:3

A novel citrinin derivative from the marine-source fungus Penicillium citrinum
原文传递
导出
摘要 从一株海洋来源真菌Penicillium citrinum中分离得到了一个结构新颖的桔霉素衍生物penicitrinol L(1)以及两个已知类似物penidicitrinin B(2)和pennicitrinone A(3)。通过一维和二维核磁以及高分辨质谱等波谱学方法确定了新化合物的结构。此外,化合物1对人白血病HL-60细胞具有中等的抑制活性,化合物3对人黑色素瘤A375细胞具有较弱的抑制活性。 A novel citrinin derivative, penicitrinol L(1), along with two known analogues, penidicitrinin B(2) and pennicitrinone A(3) were isolated from the marine-source fungus Penicillium citrinum. The structure of the new compound was elucidated by spectroscopic methods including one and two-dimensional NMR as well as high-resolution mass spectrometric analysis. Furthermore, compound 1 showed modest cytotoxic activity against HL-60 cell line and compound 3 showed weak cytotoxic activity against A375 cell line.
出处 《药学学报》 CAS CSCD 北大核心 2015年第2期203-206,共4页 Acta Pharmaceutica Sinica
基金 Project supported by the Scientific Research Foundation of Fujian Health Department(2010-2-45) the Scientific Research Foundation of Fujian Education Department(JB13323)
关键词 桔霉素衍生物 海洋真菌 次级代谢物 细胞毒活性 citrinin derivative marine-derived fungus secondary metabolite cytotoxic activity
  • 相关文献

参考文献4

二级参考文献15

  • 1时平,陈蔚文,胡晓燕,于春晓,张鹏举,姜安丽,张建业.姜黄素上调前列腺癌细胞LNCaP中maspin基因的表达[J].药学学报,2006,41(12):1152-1156. 被引量:4
  • 2王伟,张国平,宋宝安,汪华,金林红,胡德禹,杨松.O,O'-二烷基-α-(取代苯并噻唑-2-基)氨基-(取代苯基甲基)膦酸酯的合成与抗烟草花叶病毒活性[J].有机化学,2007,27(2):279-284. 被引量:24
  • 3Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J]. Cancer Res, 2004, 64: 7099-7109. 被引量:1
  • 4Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/ MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apotosis in hepatocellular carcinoma model PLC/ PRF/5 [J]. Cancer Res, 2006, 66:11851-11858. 被引量:1
  • 5Wilhelm S, Carter C, Lynch M, et al. Discover and development of sorafenib: a multikinase inhibitor for treating cancer [J]. Nat Rev Drug Discov, 2006, 5:835 -844. 被引量:1
  • 6Guida T, Anaganti S, Provitera L, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants [J]. Clin Cancer Res, 2007, 13: 3363-3369. 被引量:1
  • 7Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling [J]. Mol Cancer Ther, 2008, 7:3129-3140. 被引量:1
  • 8Ramurthy S, Subramanian S, Aikawa M, et al. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors [J]. J Med Chem, 2008, 51: 7049-7055. 被引量:1
  • 9Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in adcanced melanoma: a phase Ⅱ randomized discontinuation trial analysis [J]. Br J Cancer, 2006, 95: 581-586. 被引量:1
  • 10Qin AF, Li Y, Song HR, et al. Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazidemoiety [J].药学学报,2012,47:1623-1629. 被引量:1

共引文献6

同被引文献29

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部